3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
45
Genitourinary
6
Gastrointestinal
3
Endocrine
3
Dermatologic
2
Breast
2
Sarcoma
1
NET
1
Head & Neck
1
Conditions
Sarcoma
10
Sarcoma, Alveolar Soft Part
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Osteosarcoma
2
Neoplasms
2
Melanoma
2
Head and Neck Neoplasms
2
Gliosarcoma
2
Glioblastoma
2
Vulvar Neoplasms
1
Urogenital Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Clear Cell
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Pancreatic Neoplasms
1
Obesity
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Neoplasm Metastasis
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Liposarcoma, Myxoid
1
Liposarcoma
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Interventions
pembrolizumab
6
Magnetic Resonance Spectroscopy
6
Specimen Handling
5
Cyclophosphamide
5
Radiosurgery
3
Oncolytic Virotherapy
3
Nivolumab
3
Injections
3
Gemcitabine
3
Drug Therapy
3
Biopsy
3
fludarabine
2
belinostat
2
Riluzole
2
Paclitaxel
2
Ipilimumab
2
Filgrastim
2
Docetaxel
2
Cisplatin
2
Celecoxib
2
Carboplatin
2
Bortezomib
2
Blood Specimen Collection
2
Amifostine
2
AH 111585
2
tislelizumab
1
spartalizumab
1
seribantumab
1
selpercatinib
1
sargramostim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
atezolizumab
×
Sarcoma
×
Clear all
NCT04273061
2025-09-22
CAPTIV-8
British Columbia Cancer Agency
Phase 2
Recruiting
200 enrolled